Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 14,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $24.72, for a total value of $346,080.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.25, for a total value of $59,312.50.
• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.97, for a total value of $55,152.50.
• On Monday, January 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.81, for a total value of $51,382.50.

Enliven Therapeutics Trading Down 5.4 %

ELVN stock opened at $19.94 on Tuesday. The stock has a 50-day moving average price of $16.88 and a two-hundred day moving average price of $14.25. Enliven Therapeutics, Inc. has a 12-month low of $9.80 and a 12-month high of $26.00. The company has a market cap of $821.53 million, a PE ratio of -9.10 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. Equities analysts forecast that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ELVN. Tower Research Capital LLC TRC purchased a new stake in shares of Enliven Therapeutics in the first quarter worth about $36,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Enliven Therapeutics in the second quarter worth about $39,000. AJOVista LLC purchased a new stake in shares of Enliven Therapeutics in the fourth quarter worth about $28,000. Royal Bank of Canada boosted its position in shares of Enliven Therapeutics by 532.7% in the second quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock worth $63,000 after buying an additional 2,589 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in shares of Enliven Therapeutics in the fourth quarter worth about $66,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analysts Set New Price Targets

Separately, Mizuho began coverage on Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price target for the company.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.